A patient receives a prescription for depot injection of risperidone. What teaching should the nurse provide regarding the onset of therapeutic effects?

Choice A reason: Risperidone long-acting injection utilizes microsphere technology that requires a significant lag time for the polymer to degrade and release the active medication. Consequently, therapeutic plasma levels are typically not reached for 3 to 4 weeks, necessitating oral supplementation during the initial induction phase to maintain clinical stability. Choice B reason: Immediate therapeutic effects are physiologically impossible with depot risperidone formulations due to the slow-release matrix design. Unlike immediate-release aqueous injections used for acute agitation, the depot form is engineered for sustained maintenance therapy and lacks the rapid bioavailability required to produce an instantaneous reduction in psychotic symptoms. Choice C reason: Full clinical effects are not observed after a single dose because the steady-state concentration of the drug is only achieved after multiple sequential injections. The titration of the medication within the systemic circulation occurs gradually, and clinical improvement is usually assessed over a period of several months. Choice D reason: The pharmacokinetics of depot risperidone are specifically designed to provide a duration of action far exceeding 24 hours, usually lasting 2 weeks per injection. If the effects dissipated within 1 day, the medication would fail its primary purpose of improving adherence and providing stable neuroleptic coverage.